Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Seres Therapeutics (MCRB) Asset Writedowns and Impairment (2024)

Seres Therapeutics (MCRB) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $3.3 million as the latest value for Q1 2024.

Quarterly Asset Writedowns and Impairment changed N/A to $3.3 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2024, changed N/A year-over-year, with the annual reading at $3.3 million for FY2024, N/A changed from the prior year.
Asset Writedowns and Impairment hit $3.3 million in Q1 2024 for Seres Therapeutics.
In the past five years, Asset Writedowns and Impairment ranged from a high of $3.3 million in Q1 2024 to a low of $3.3 million in Q1 2024.